TG Therapeutics TGTX shares ended the last trading session 7.5% higher at $29.74. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 19.6% loss over the past four weeks.
This jump in share price came after management reported preliminary sales of its sole-marketed drug Briumvi for the full year 2024. TGTX claims to have added $310 million from the drug’s sales in 2024, surpassing management’s prior expectation of $300-$305 million. Management also provided an encouraging outlook for 2025, expecting to record $540 million in total revenues.
This biopharmaceutical company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents a year-over-year change of +177.8%. Revenues are expected to be $96.61 million, up 119.7% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For TG Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
TG Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Puma Biotech PBYI, finished the last trading session 0.3% higher at $3.09. PBYI has returned 2.7% over the past month.
Puma Biotech's consensus EPS estimate for the upcoming report has changed +50% over the past month to $0.14. Compared to the company's year-ago EPS, this represents a change of -54.8%. Puma Biotech currently boasts a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report
Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.